Your browser doesn't support javascript.
loading
Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín, Hassiel Aurelio; Tosti, Antonella.
Afiliação
  • Ramírez-Marín HA; Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.
  • Tosti A; Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Expert Opin Emerg Drugs ; 27(4): 379-387, 2022 12.
Article em En | MEDLINE | ID: mdl-36408593
INTRODUCTION: Alopecia Areata (AA) is the second most common non-scarring hair loss disorder, with a prevalence of 1 in 1000 and a lifetime incidence of 2% worldwide. Data from a recent American study shows that from 68,121 patients with the diagnosis of AA, 37,995 (55.8%) were prescribed treatment for AA within a year of diagnosis, however there are still no therapies able to induce permanent remission, or treatments that guarantee hair regrowth/remissions in 100% of cases, especially in longstanding/severe AA. Recently, oral baricitinib has been approved for AA, being the first drug approved for this specific indication. AREAS COVERED: The current review will provide a summary of current pharmacological approaches and novel therapeutics in development. EXPERT OPINION: New and very effective drugs have become available for the treatment of severe AA, and many others are expected soon. However, even new, effective treatments are not effective in all patients and recurrence rates after treatment interruption are high. AA is a systemic disease with important impact on quality of life and should not be considered just as an aesthetic problem. Treatment of the disease should take in account and possibly also address treatment of comorbidities.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alopecia em Áreas / Inibidores de Janus Quinases Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Alopecia em Áreas / Inibidores de Janus Quinases Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article